Navigation Links
VirtualScopics to Present at the 14th Annual BIO CEO & Investor Conference
Date:2/10/2012

ROCHESTER, N.Y., Feb. 10, 2012 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that Mr. Jeff Markin, the company's president and chief executive officer, will be presenting a corporate overview at the upcoming 14th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Mr. Markin's presentation will be on Monday, February 13, 2012 at 4:30 PM ET.

A live webcast of the presentation will be available for 30 days in the Investor Relations section of the company's website, www.virtualscopics.com.

About VirtualScopics, Inc.VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2008 and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2010 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov . These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACT:Investor Relations:Company Contact: 

Tim Ryan

Molly Henderson 

The Shoreham Group

Chief Business and Financial Officer, Sr. Vice President 

80 Eighth Ave, Ste 1107

500 Linden Oaks 

New York, NY 10011

Rochester, New York 14625 

+1 212 242 7777 Direct

+1 585 249.6231 

tryan@shorehamgroupllc.com

 


'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
6. VirtualScopics Receives Issuance in Japan of Prominent Patent
7. VirtualScopics Added to Russell Microcap Index
8. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
9. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
10. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
11. VirtualScopics Revenues Hit Another Quarterly Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb. 24, 2017 Research ... Health Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 23.8% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow ... approximately $2.9 billion by 2025. This industry report analyzes ... as well as regional levels presented in the research scope. The study ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... , ... IndustryArchive.Org . is announcing a new way for B2B Sellers ... only pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase ... reality that B2B buyers are controlling the sales process via the Internet and that ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the 10th ... Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on how ... management. , ODH will also have an exhibit booth where attendees may speak to ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide ... with a specific LRRK2 mutation, according to a study released today at the ... evidence of a link between pesticides and incidence of sporadic PD through occupational ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
Breaking Medicine News(10 mins):